Chloroquine was shown in 2004 to be active in vitro against SARS coronavirus but is of unproven efficacy and safety in patients infected with SARS-CoV-2. The drug’s potential benefits and risks for COVID-19 patients, without and with azithromycin, is discussed by Dr. David Juurlink, head of the Division of Clinical Pharmacology and Toxicology at Sunnybrook Health Sciences Centre in Toronto.
Latest posts by Hippocratic Post (see all)
- Pilot whole genome sequencing service - 22nd October 2024
- Coping with SAD: A guide for university students - 22nd October 2024
- Plugging into pain: ant toxin causes electrical sting - 18th October 2024
Leave a Reply
You must be logged in to post a comment.